Navigation Links
BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
Date:5/28/2008

n. "The combination of a PARP inhibitor such as BSI-201 which specifically targets uterine tumors in a unique way may boost the effects of common chemotherapy regimen. We hope this drug will play a transformative role in the way we approach treatment."

Uterine cancer is the most common gynecological tumor, and the fourth most-common type of tumor in women. Forty thousand new diagnoses are made each year in the United States.

"Because PARP is expressed at high levels in uterine cancer and particularly MMT, we believe that BSI-201 has the potential to selectively target these highly aggressive and poorly treated tumors," said BiPar Executive Vice President Barry Sherman, M.D. "This will be our third study designed around our gene expression data, which has been invaluable in selecting types of cancer that will most likely respond to PARP inhibition."

About BiPar Sciences

BiPar Sciences is a drug development company with a therapeutic focus on exploring novel mechanisms of action in oncology. The lead development program is based on DNA repair, specifically with poly ADP-ribose polymerase (PARP) inhibitors. The lead product within that program is BSI-201, a platform drug with the potential to be a superior new treatment across a range of tumor types, both as monotherapy and in combination with chemotherapy. The company is currently testing BSI-201 in a range of Phase 2 trials in breast, brain, uterine and ovarian cancer.


'/>"/>
SOURCE BiPar Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2

Related medicine technology :

1. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
2. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
3. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
4. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
5. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
6. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
7. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
8. Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives
9. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
10. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
11. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 2013 , Safinamide significantly ... patients as add-on to levodopa Safinamide ... symptoms in fluctuating PD patients as add-on to ... S.p.A. ("Newron"), a research and development company focused ... partner Zambon S.p.A., a pharmaceutical company strongly committed ...
(Date:6/18/2013)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... public offering of common shares (the "Offering"). Pursuant to ... at a price of $85.00 per share, for aggregate ... file a final prospectus supplement to its effective shelf ... similar filing with the securities regulatory authorities in each ...
(Date:6/18/2013)... , June 18, 2013  It has ... of Alliance Seating and Mobility, a subsidiary company ... access timely repair. This appears to be due ... reduction of field service employees.  ... great many of these clients are complex mobility ...
Breaking Medicine Technology:Safinamide Phase III Study Results Presented at 2013 MDS Meeting 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 3Safinamide Phase III Study Results Presented at 2013 MDS Meeting 4Safinamide Phase III Study Results Presented at 2013 MDS Meeting 5Safinamide Phase III Study Results Presented at 2013 MDS Meeting 6Valeant Pharmaceuticals Prices Public Offering Of Common Shares 2Valeant Pharmaceuticals Prices Public Offering Of Common Shares 3Valeant Pharmaceuticals Prices Public Offering Of Common Shares 4
(Date:6/19/2013)... (PRWEB) June 19, 2013 Blueforce ... and sensor machine software, today announced it has ... its Decentralized Fusion Engine technology. The award ... the acquisition of key strategic partnerships. , ... wireless collaboration and machine-to-machine (M2M) software products that ...
(Date:6/19/2013)... A blow to the head; a swift jarring to ... to hours. It’s understandable, but what else may follow ... traumatic brain injury. According to mayoclinic.com , usual ... But many other symptoms may follow, sometimes not for ... include ongoing headaches, dizziness, feeling like you’re in a fog, ...
(Date:6/19/2013)... 19, 2013 Walkingspree, a specialized wellness ... the launch of its new Facebook App. This is ... inspire participants to reach their program fitness goals. Consistent ... Walkingspree clients are given more tools to customize their ... , Corporate clients may choose whether or not they ...
(Date:6/19/2013)... Weight gain and obesity have been ... including heart disease, kidney failure and high blood pressure. ... and unnecessary fat, have many people searching for fast ... diets to not only allow patients to succeed ... aim to reduce the risk for many weight-related health ...
(Date:6/19/2013)... June 19, 2013 The reason for the ... because users can place a 4x8 flood tray inside the ... to work around. In addition, Gorilla Grow Tents are ... are the tallest, thickest and strongest grow tents on the ... grow tent standards. , Gorilla Grow Tents are ...
Breaking Medicine News(10 mins):Health News:Blueforce Awarded Patent for Decentralized Sensor Fusion 2Health News:Concussions Can Lead to Much More Than a Headache, According to MMTR Health Inc. Founder, Terry Moore, Neuromuscular and Cardiovascular Physiologist 2Health News:Walkingspree’s New Facebook Connectivity Boosts Accountability and Engagement 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers New Fast Weight Loss Programs for Patients Suffering with Health Care Concerns 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers New Fast Weight Loss Programs for Patients Suffering with Health Care Concerns 3Health News:Stealth Grow Tent Brand’s Popularity Rises 2
... disused proteins are eliminated by a cellular shredder called ... to dispose with Ubiquitin (Ub) in order to avoid ... in the ubiquitin-proteasome system can be fatal for the ... disorders but also developmental defects are the consequences. The ...
... the first scientific review of a dozen patients who have ... gene therapy technique is safe and may be effective at ... patients, half of whom live on Long Island, are in ... to medicines when they signed on for the experimental therapy. ...
... on June 26, after spending 23 days in the slammer. ... Angeles County Sheriff's Department's Inmate Reception Center. ,The exact ... ,Although her sentence was for 45 days, authorities have said ... good behaviour. ,"There was some confusion as to whether ...
... new details about how proteins used to destroy bacteria ... ,Gunnar K. Gouras, associate professor of neurology and ... York, and colleagues provide new insights into how these ... disease and raise hopes for a vaccine against the ...
... a credible scientific method for testing and measuring ... on XanGo Juice , indicate usage of the ... to high xanthone absorption. ,XanGo, LLC, ... leading scientific exploration of the whole mangosteen fruit ...
... is making all possible arrangements to look good on her yet ... thing that the socialite will do after being released on June ... complained to the press while in jail that she's not permitted ... going dry. ,So, the heiress has booked a facial ...
Cached Medicine News:Health News:Protein Targets for Carcinogenesis 2Health News:Gene Therapy for Parkinsons Disease 2Health News:Researchers Link Bacteria Destroying Proteins to Alzheimer's Treatment 2Health News:Researchers Link Bacteria Destroying Proteins to Alzheimer's Treatment 3Health News:New Technique to Measure Xanthone in Mangosteen 2Health News:New Technique to Measure Xanthone in Mangosteen 3
Blunt Weitlaner Retractor....
Weitlaner Beckmann retractor, sharp prongs, SS....
Baby Weitlaner retractor, blunt, 4"....
Scoville sharp curette, 10, straight, scoop size 4 x 10 mm....
Medicine Products: